Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
March 04, 2019 09:15 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Advances commercialization strategy for lenabasum ahead of data readouts of key registrational studies in 2020, and potential U.S. Food and Drug Administration (“FDA”) approval and launch in 2021Mr....
Corbus Pharmaceuticals Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
February 28, 2019 13:49 ET
|
Block & Leviton LLP
BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Corbus Pharmaceuticals...
Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
January 30, 2019 07:30 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s leading...
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 25, 2019 09:01 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Jan. 25, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s leading...
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 24, 2019 16:01 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s...
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
January 03, 2019 10:01 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Collaboration in-line with Corbus vision to become the global leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemAdvances strategy to partner...
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
December 18, 2018 08:46 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemLenabasum in late-stage clinical studies in three orphan...
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
December 17, 2018 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare...
Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
November 08, 2018 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Licensed Jenrin Discovery’s extensive library of small molecules targeting the endocannabinoid system (ECS) positioning Corbus with the leading pipeline focused on treating inflammatory and fibrotic...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
November 06, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT – – 30th Annual Piper Jaffray Healthcare Conference presentation with...